-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to actively promote the development of clinical oncology in my country, improve the clinical and scientific research level of clinical oncologists, and further promote the formulation and promotion of CSCO guidelines for diagnosis and treatment, the Chinese Society of Clinical Oncology (CSCO) held a meeting in Beijing on April 23-24, 2021.
The 2021 CSCO Guidelines Conference will be held in a combination of online and offline methods.
At this meeting, Professor Xu Lanping from Peking University People's Hospital interpreted the "Guidelines for the Treatment of Leukemia and Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation".
Yimaitong organized the main contents as follows.
The 2021 edition of the "Guidelines for the Treatment of Leukemia and Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation" contains 11 topics, reflecting the concept of "full management".
Topic 1: Indications and Timeliness 2021 "Guidelines for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Leukemia and Myelodysplastic Syndrome" is divided into multi-level catalogs.
The first-level catalog of acute myeloid leukemia (AML) in topic 1 is classified as acute according to disease classification.
Promyelocytic leukemia (APL) and non-APL, the secondary category is divided into first complete remission (CR1), second or more complete remission (≥CR2) and relapse and refractory (R/R) according to the disease status.
) Patients; the first-level catalog of acute lymphoblastic leukemia (ALL) is divided into Philadelphia chromosome-positive (PH+) ALL and PH- ALL according to disease classification, and the second-level catalog is divided into adults, adolescents and children according to age stratification, and the third-level catalog is based on Disease status is divided into CR1, ≥CR2 and R/R patients; the first-level catalog of chronic myeloid leukemia (CML) is divided into chronic phase (CP), accelerated phase (AP), and blast phase (BC) according to disease classification; bone marrow hyperplasia The first-level catalog of abnormal syndromes (MDS) is divided into higher-risk groups and lower-risk groups according to the MDS stratification.
Topic 2: Donor selection In Topic 2, the selection of donor sources is based on the classification of HLA full-phase contracted sibling donors, haplotype-matched donors, non-blood-related voluntary donors, and non-blood-related cord blood donors, and the best donor for the patient The selection was guided.
Topic 3: Evaluation Topic 3 introduces the relevant evaluation and examination contents of patients and donors before transplantation.
Topic 4: Pretreatment Topic 4 introduces pretreatment programs for different diseases, including standard myeloablative (MAC) pretreatment programs, reduced toxicity (RTC), reduced intensity (RIC), and non-myeloablative (NMA) pretreatment programs.
Treatment plan, enhanced pretreatment and intensive chemotherapy sequential transplantation pretreatment plan.
Topic 5: Pretreatment Topic 5 provides guidance on donor mobilization, cell collection and reinfusion for allogeneic hematopoietic stem cell transplantation.
Topic 6: aGVHD Topic 6 provides guidance on preventive drugs, medication methods, diagnosis and grading standards, and therapeutic drug recommendations for acute inhibitor versus host disease (aGVHD).
Topic 7: cGVHD Topic 7 provides guidance on the prevention, diagnosis, first-line treatment, and second-line treatment of chronic GVHD (cGVHD).
Topic 8: Fungal Infections Topic 8 introduces the prevention and treatment of fungal infections.
Topic 9: Viral infections Topic 9 mainly introduces viral infections, among which hepatitis B virus (HBV) mainly introduces HBV reactivation/infection and disease monitoring after transplantation, transplant timing of HBV infected patients, and HBV reactivation in transplant patients / Prevention and treatment of infection; Cytomegalovirus (CMV) mainly introduces CMV infection/reactivation and disease monitoring in transplantation, early treatment of CMV infection/reactivation, treatment of CMV disease, CMV resistance; Epstein-Barr virus (EBV) mainly It introduces the reactivation of EBV after transplantation and the monitoring of the disease, the prevention of EBV reactivation, the preemptive treatment of EBVemia, and the treatment of EBV-related lymphoproliferative disease (EBV-PTLD)/other end-organ diseases after transplantation.
Topic 10: Recurrence Topic 10 provides guidance on the diagnosis and treatment of disease recurrence from four aspects: minimal residual disease (MRD), prevention, preemptive treatment, and treatment.
Topic 10 mainly introduces the commonly used MRD detection methods and the criteria for judging MRD positive for MRD; prevention, preemptive treatment, and treatment respectively prevent recurrence of AML, ALL, MDS, and CML after transplantation, preemptive treatment for recurrence after transplantation, and transplantation The treatment of post-relapse is guided.
Topic 11: Follow-up Topic 11 is classified according to the length of transplantation (discharge to 100 days, 3 months later, long-term), and recommends and guides the frequency and content of follow-up respectively.
In addition to 11 topics, this guide also contains 19 appendices.
Professor Xu Lanping finally stated that since the 2021 edition of the "Guidelines for the Treatment of Leukemia and Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation" is the first edition of the guide, I hope that colleagues can provide more feedback and guide the subsequent update of the guide.
Poke "read the original text" and we will make progress together
The 2021 CSCO Guidelines Conference will be held in a combination of online and offline methods.
At this meeting, Professor Xu Lanping from Peking University People's Hospital interpreted the "Guidelines for the Treatment of Leukemia and Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation".
Yimaitong organized the main contents as follows.
The 2021 edition of the "Guidelines for the Treatment of Leukemia and Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation" contains 11 topics, reflecting the concept of "full management".
Topic 1: Indications and Timeliness 2021 "Guidelines for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Leukemia and Myelodysplastic Syndrome" is divided into multi-level catalogs.
The first-level catalog of acute myeloid leukemia (AML) in topic 1 is classified as acute according to disease classification.
Promyelocytic leukemia (APL) and non-APL, the secondary category is divided into first complete remission (CR1), second or more complete remission (≥CR2) and relapse and refractory (R/R) according to the disease status.
) Patients; the first-level catalog of acute lymphoblastic leukemia (ALL) is divided into Philadelphia chromosome-positive (PH+) ALL and PH- ALL according to disease classification, and the second-level catalog is divided into adults, adolescents and children according to age stratification, and the third-level catalog is based on Disease status is divided into CR1, ≥CR2 and R/R patients; the first-level catalog of chronic myeloid leukemia (CML) is divided into chronic phase (CP), accelerated phase (AP), and blast phase (BC) according to disease classification; bone marrow hyperplasia The first-level catalog of abnormal syndromes (MDS) is divided into higher-risk groups and lower-risk groups according to the MDS stratification.
Topic 2: Donor selection In Topic 2, the selection of donor sources is based on the classification of HLA full-phase contracted sibling donors, haplotype-matched donors, non-blood-related voluntary donors, and non-blood-related cord blood donors, and the best donor for the patient The selection was guided.
Topic 3: Evaluation Topic 3 introduces the relevant evaluation and examination contents of patients and donors before transplantation.
Topic 4: Pretreatment Topic 4 introduces pretreatment programs for different diseases, including standard myeloablative (MAC) pretreatment programs, reduced toxicity (RTC), reduced intensity (RIC), and non-myeloablative (NMA) pretreatment programs.
Treatment plan, enhanced pretreatment and intensive chemotherapy sequential transplantation pretreatment plan.
Topic 5: Pretreatment Topic 5 provides guidance on donor mobilization, cell collection and reinfusion for allogeneic hematopoietic stem cell transplantation.
Topic 6: aGVHD Topic 6 provides guidance on preventive drugs, medication methods, diagnosis and grading standards, and therapeutic drug recommendations for acute inhibitor versus host disease (aGVHD).
Topic 7: cGVHD Topic 7 provides guidance on the prevention, diagnosis, first-line treatment, and second-line treatment of chronic GVHD (cGVHD).
Topic 8: Fungal Infections Topic 8 introduces the prevention and treatment of fungal infections.
Topic 9: Viral infections Topic 9 mainly introduces viral infections, among which hepatitis B virus (HBV) mainly introduces HBV reactivation/infection and disease monitoring after transplantation, transplant timing of HBV infected patients, and HBV reactivation in transplant patients / Prevention and treatment of infection; Cytomegalovirus (CMV) mainly introduces CMV infection/reactivation and disease monitoring in transplantation, early treatment of CMV infection/reactivation, treatment of CMV disease, CMV resistance; Epstein-Barr virus (EBV) mainly It introduces the reactivation of EBV after transplantation and the monitoring of the disease, the prevention of EBV reactivation, the preemptive treatment of EBVemia, and the treatment of EBV-related lymphoproliferative disease (EBV-PTLD)/other end-organ diseases after transplantation.
Topic 10: Recurrence Topic 10 provides guidance on the diagnosis and treatment of disease recurrence from four aspects: minimal residual disease (MRD), prevention, preemptive treatment, and treatment.
Topic 10 mainly introduces the commonly used MRD detection methods and the criteria for judging MRD positive for MRD; prevention, preemptive treatment, and treatment respectively prevent recurrence of AML, ALL, MDS, and CML after transplantation, preemptive treatment for recurrence after transplantation, and transplantation The treatment of post-relapse is guided.
Topic 11: Follow-up Topic 11 is classified according to the length of transplantation (discharge to 100 days, 3 months later, long-term), and recommends and guides the frequency and content of follow-up respectively.
In addition to 11 topics, this guide also contains 19 appendices.
Professor Xu Lanping finally stated that since the 2021 edition of the "Guidelines for the Treatment of Leukemia and Myelodysplastic Syndrome with Allogeneic Hematopoietic Stem Cell Transplantation" is the first edition of the guide, I hope that colleagues can provide more feedback and guide the subsequent update of the guide.
Poke "read the original text" and we will make progress together
